142 related articles for article (PubMed ID: 33869274)
1. An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma.
Zhang H; Shi Q; Yang Z; Wang K; Zhang Z; Huang Z; Cui X; Li F
Front Mol Biosci; 2021; 8():598427. PubMed ID: 33869274
[TBL] [Abstract][Full Text] [Related]
2. Protein-coding genes combined with long non-coding RNAs predict prognosis in esophageal squamous cell carcinoma patients as a novel clinical multi-dimensional signature.
Guo JC; Li CQ; Wang QY; Zhao JM; Ding JY; Li EM; Xu LY
Mol Biosyst; 2016 Oct; 12(11):3467-3477. PubMed ID: 27714034
[TBL] [Abstract][Full Text] [Related]
3. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma.
Huang GW; Xue YJ; Wu ZY; Xu XE; Wu JY; Cao HH; Zhu Y; He JZ; Li CQ; Li EM; Xu LY
BMC Cancer; 2018 Feb; 18(1):147. PubMed ID: 29409459
[TBL] [Abstract][Full Text] [Related]
4. A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment.
Gao J; Tang T; Zhang B; Li G
Front Oncol; 2021; 11():603634. PubMed ID: 33718151
[TBL] [Abstract][Full Text] [Related]
5. Identification of a nomogram based on long non-coding RNA to improve prognosis prediction of esophageal squamous cell carcinoma.
Li W; Liu J; Zhao H
Aging (Albany NY); 2020 Jan; 12(2):1512-1526. PubMed ID: 31978896
[TBL] [Abstract][Full Text] [Related]
6. A Novel Clinical Six-Flavoprotein-Gene Signature Predicts Prognosis in Esophageal Squamous Cell Carcinoma.
Peng L; Guo JC; Long L; Pan F; Zhao JM; Xu LY; Li EM
Biomed Res Int; 2019; 2019():3869825. PubMed ID: 31815134
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Significance of Metabolic Syndrome and a Related Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma.
Liu Y; Wang L; Liu H; Li C; He J
Front Oncol; 2020; 10():61. PubMed ID: 32133283
[No Abstract] [Full Text] [Related]
8. A five-gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma.
He W; Yan Q; Fu L; Han Y
Oncol Lett; 2019 Aug; 18(2):1381-1387. PubMed ID: 31423201
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Long Non-coding RNA Signature and Clinical Nomogram to Evaluate Survival of Patients Suffering Esophageal Squamous Cell Carcinoma.
Zhu T; Ma Z; Wang H; Wei D; Wang B; Zhang C; Fu L; Li Z; Yu G
Front Cell Dev Biol; 2021; 9():641960. PubMed ID: 33748133
[TBL] [Abstract][Full Text] [Related]
10. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
11. Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.
Chen RL; Zhou JX; Cao Y; Sun LL; Su S; Deng XJ; Lin JT; Xiao ZW; Chen ZZ; Wang SY; Lin LZ
Front Immunol; 2020; 11():1933. PubMed ID: 33072067
[TBL] [Abstract][Full Text] [Related]
12. A Novel Ras--Related Signature Improves Prognostic Capacity in Oesophageal Squamous Cell Carcinoma.
Yang HS; Liu W; Zheng SY; Cai HY; Luo HH; Feng YF; Lei YY
Front Genet; 2022; 13():822966. PubMed ID: 35281814
[TBL] [Abstract][Full Text] [Related]
13. Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma.
Zuo Z; Xiong J; Zeng C; Jiang Y; Xiong K; Tao H; Guo Y
Front Mol Biosci; 2021; 8():625470. PubMed ID: 33748188
[No Abstract] [Full Text] [Related]
14. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
15. RNA sequencing reveals the expression profiles of circRNA and identifies a four-circRNA signature acts as a prognostic marker in esophageal squamous cell carcinoma.
Wang W; Zhu D; Zhao Z; Sun M; Wang F; Li W; Zhang J; Jiang G
Cancer Cell Int; 2021 Mar; 21(1):151. PubMed ID: 33663506
[TBL] [Abstract][Full Text] [Related]
16. Stratification From Heterogeneity of the Cell-Death Signal Enables Prognosis Prediction and Immune Microenvironment Characterization in Esophageal Squamous Cell Carcinoma.
Zhang Y; Chen Y
Front Cell Dev Biol; 2022; 10():855404. PubMed ID: 35493093
[TBL] [Abstract][Full Text] [Related]
17. An Immune Cell-Based Signature Associating With EMT Phenotype Predicts Postoperative Overall Survival of ESCC.
Yu H; Gu D; Yue C; Xu J; Yan F; He X
Front Oncol; 2021; 11():636479. PubMed ID: 33869022
[TBL] [Abstract][Full Text] [Related]
18. Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis.
Chen Q; Qiu B; Zeng X; Hu L; Huang D; Chen K; Qiu X
Cancer Cell Int; 2021 Mar; 21(1):182. PubMed ID: 33766042
[TBL] [Abstract][Full Text] [Related]
19. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma.
Abudureheman A; Ainiwaer J; Hou Z; Niyaz M; Turghun A; Hasim A; Zhang H; Lu X; Sheyhidin I
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1025-1035. PubMed ID: 29532228
[TBL] [Abstract][Full Text] [Related]
20. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma.
Zhou X; Wen W; Zhu J; Huang Z; Zhang L; Zhang H; Qi LW; Shan X; Wang T; Cheng W; Zhu D; Yin Y; Chen Y; Zhu W; Shu Y; Liu P
Oncotarget; 2017 May; 8(21):34468-34480. PubMed ID: 28380431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
